|
| First author, publication year | Number of surgical patients | Median followup, months | Survival data | Predictors of survival |
|
| Mayo, 2011 [14] | 339
(66 with simultaneous ablation) | 26 | Median OS: 123 months
5-year survival: 74% | High-volume (>25% liver involved) and symptomatic disease benefited most from surgery (versus intra-arterial therapy, ) |
|
| Saxena, 2011 [15] | 74
(38 with simultaneous cryoablation) | 41 | Median PFS: 23 months
Median OS: 95 months | PFS: pathologic margin status ()
OS: grade (), extrahepatic disease () |
|
| Karabulut, 2011 [16] | 27 | 29 | Median PFS: 15 months
Median OS: 190 months | Improved OS with resection of primary tumor () |
|
| Glazer, 2010 [17] | 172
(120 with small bowel or pancreatic primaries; 18 had only RFA) | 50 | Median OS: 116 months
5-year survival: 77.4%
10-year survival: 50.4% | Increasing interval from primary resection to hepatic metastases predicted for poorer survival () |
|
| Fischer, 2008 [18] | 118 | 20 | 5-year survival: 44% for well-differentiated neuroendocrine carcinoma versus 0% for poorly-differentiated | In well-differentiated carcinomas, any resection (R0 versus R1/2) significantly increased survival () |
|
| Osborne, 2006 [19] | 70 | | Mean OS: 50 months for complete cytoreduction (versus 32 months for palliative cytoreduction) | |
|
| Sarmiento, 2003 [20] | 170
(75 with complete resection) | | Median OS: 81 months | |
|
| Elias, 2003 [21] | 47
(36 with concurrent extrahepatic resection) | 62 | Median OS: 91 months
5-year survival: 71% | DFS: completeness of surgery (R0 versus R1 versus R2) (), pancreatic origin (), bilateral liver involvement () |
|
| Chen, 1998 [22] | 15 | | 5-year survival: 73% (versus 29% in 23 patients with unresectable disease) | |
|
